Your browser doesn't support javascript.
loading
Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis.
Priantti, Jonathan N; Rodrigues, Natasha Maranhão Vieira; de Moraes, Francisco Cezar Aquino; da Costa, Allyson Guimarães; Jezini, Deborah Laredo; Heckmann, Maria Izabel Ovellar.
Afiliación
  • Priantti JN; Department of Internal Medicine, School of Medicine, Federal University of Amazonas - UFAM, Manaus, AM, 69020-160, Brazil. jonathan.priantti@gmail.com.
  • Rodrigues NMV; Department of Internal Medicine, School of Medicine, Federal University of Amazonas - UFAM, Manaus, AM, 69020-160, Brazil.
  • de Moraes FCA; Oncology Research Center, Federal University of Pará, Belém, PA, 66073-005, Brazil.
  • da Costa AG; School of Nursing, Federal University of Amazonas - UFAM, Manaus, AM, 69057-070, Brazil.
  • Jezini DL; Department of Internal Medicine, School of Medicine, Federal University of Amazonas - UFAM, Manaus, AM, 69020-160, Brazil.
  • Heckmann MIO; Department of Education and Research, Hospital Universitário Getúlio Vargas, Manaus, AM, 69020-170, Brazil.
Endocrine ; 86(1): 284-292, 2024 Oct.
Article en En | MEDLINE | ID: mdl-38709445
ABSTRACT

PURPOSE:

Approximately 45% of anaplastic thyroid cancer (ATC) patients harbor a BRAFV600E mutation and are eligible for target therapy (TT) with BRAF and MEK inhibitors (BRAFi/MEKi), nevertheless, few data advocate for this. Hence, we've conducted a systematic review and meta-analysis investigating the effectiveness and safety of BRAFi/MEKi in BRAFV600E ATC patients.

METHODS:

PubMed, Embase, and the Cochrane Library were systematically searched for BRAFi/MEKi TT in BRAFV600E ATC patients. Outcomes included objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), duration of response (DOR) and adverse events (AEs).

RESULTS:

Nine studies with 168 patients were included. Median follow-up ranged from 2.0 to 47.9 months. 75% of patients had stage IVc. In a pooled analysis, ORR was 68.15% (95% CI 55.31-80.99, I2 = 47%) and DCR was 85.39% (95% CI 78.10-92.68, I2 = 0), with a median DOR of 14.4 months (95% CI 4.6-14.4) and a median PFS of 6.7 months (95% CI 4.7-34.2). Moreover, 1-year OS rate was 64.97% (95% CI 48.76-81.17, I2 = 84%) and 2-years OS rate was 52.08% (95% CI 35.71-68.45, I2 = 79%). Subgroup analysis showed patients in the neoadjuvant setting had higher rates of 1 and 2-years OS and observational studies tended to report higher rates of ORR than clinical trials. No new or unexpected adverse events were found.

CONCLUSIONS:

Our study demonstrated BRAFi/MEKi have a decent activity for BRAFV600E ATC patients, especially in the neoadjuvant setting, with a tolerable safety profile. However, further clinical trials are warranted to investigate these findings.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Tiroides / Proteínas Proto-Oncogénicas B-raf / Inhibidores de Proteínas Quinasas / Carcinoma Anaplásico de Tiroides Límite: Humans Idioma: En Revista: Endocrine Asunto de la revista: ENDOCRINOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Tiroides / Proteínas Proto-Oncogénicas B-raf / Inhibidores de Proteínas Quinasas / Carcinoma Anaplásico de Tiroides Límite: Humans Idioma: En Revista: Endocrine Asunto de la revista: ENDOCRINOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Estados Unidos